Immunotherapeutic potential for ceramide-based activators of iNKT cells

Trends in Pharmacological Sciences

Volumn 26, Issue 5, 2005, Pages 252-257

  Berkers, Celia R ^a   Ovaa, Huib ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; GLYCOLIPID; IMMUNOMODULATING AGENT;

AUTOIMMUNE DISEASE; CANCER; CELL DIFFERENTIATION; CELL SUBPOPULATION; CYTOKINE PRODUCTION; DRUG EFFICACY; HELPER CELL; HUMAN; IN VIVO STUDY; INFECTION; LIPOGENESIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 18044392378     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.03.005     Document Type: Review

References (55)

1. T. Natori Agelasphins, novel -galactosylceramides from the marine sponge Agelas mauritianus Tetrahedron Lett. 34 1993 5591 5592
2. T. Natori Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus Tetrahedron 50 1994 2771 2784
3. M. Morita Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice J. Med. Chem. 38 1995 2176 2187
4. Y. Hayakawa Alpha-galactosylceramide: potential immunomodulatory activity and future application Curr. Med. Chem. 11 2004 241 252
5. S.B. Wilson, and T.L. Delovitch Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity Nat. Rev. Immunol. 3 2003 211 222
6. M. Taniguchi The regulatory role of Valpha14 NKT cells in innate and acquired immune response Annu. Rev. Immunol. 21 2003 483 513
7. L. Van Kaer Natural killer T cells as targets for immunotherapy of autoimmune diseases Immunol. Cell Biol. 82 2004 315 322
8. T. Kawano CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides Science 278 1997 1626 1629
9. K. Miyamoto A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells Nature 413 2001 531 534
10. J. Schmieg Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha- Galactosylceramide J. Exp. Med. 198 2003 1631 1641
11. G. Yang The C-glycoside analogue of the immunostimulant alpha-galactosylceramide (KRN7000): synthesis and striking enhancement of activity Angew. Chem. Int. Ed. Engl. 43 2004 3818 3822
12. G. Chen Efficient synthesis of alpha-C-galactosyl ceramide immunostimulants: use of ethylene-promoted olefin cross-metathesis Org. Lett. 6 2004 4077 4080
13. M. Brigl, and M.B. Brenner CD1: antigen presentation and T cell function Annu. Rev. Immunol. 22 2004 817 890
14. D.M. Zajonc Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A Nat. Immunol. 4 2003 808 815
15. Z. Zeng Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove Science 277 1997 339 345
16. C.C. Dascher, and M.B. Brenner Evolutionary constraints on CD1 structure: insights from comparative genomic analysis Trends Immunol. 24 2003 412 418
17. S. Sidobre, and M. Kronenberg CD1 tetramers: a powerful tool for the analysis of glycolipid-reactive T cells J. Immunol. Methods 268 2002 107 121
18. T. Kawano Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells Cancer Res. 59 1999 5102 5105
19. P.R. Rogers Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000 J. Immunol. Methods 285 2004 197 214
20. N.Y. Crowe Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells J. Immunol. 171 2003 4020 4027
21. M. Harada Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation Int. Immunol. 16 2004 241 247
22. M.T. Wilson The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion Proc. Natl. Acad. Sci. U. S. A. 100 2003 10913 10918
23. S. Sharif Activation of natural killer T cells by alpha- galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes Nat. Med. 7 2001 1057 1062
24. A.K. Singh Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis J. Exp. Med. 194 2001 1801 1811
25. A.W. Jahng Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis J. Exp. Med. 194 2001 1789 1799
26. E. Pal Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells J. Immunol. 166 2001 662 668
27. G. Giaccone A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors Clin. Cancer Res. 8 2002 3702 3709
28. S. Fujii Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs Nat. Immunol. 3 2002 867 874
29. D. Hashimoto Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells J. Immunol. 174 2005 551 556
30. K. Fischer Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 10685 10690
31. J.L. Amprey A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan J. Exp. Med. 200 2004 895 904
32. L. Schofield CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells Science 283 1999 225 229
33. S. Joyce Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol Science 279 1998 1541 1544
34. A. Molano Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses J. Immunol. 164 2000 5005 5009
35. D.O. Procopio Glycosylphosphatidylinositol-anchored mucin-like glycoproteins from Trypanosoma cruzi bind to CD1d but do not elicit dominant innate or adaptive immune responses via the CD1d/NKT cell pathway J. Immunol. 169 2002 3926 3933
36. J.F. Romero CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice Parasite Immunol. 23 2001 267 269
37. D.Y. Wu Cross-presentation of disialoganglioside GD3 to natural killer T cells J. Exp. Med. 198 2003 173 181
38. D. Zhou Lysosomal glycosphingolipid recognition by NKT cells Science 306 2004 1786 1789
39. S. Sidobre The T cell antigen receptor expressed by Valpha14i NKT cells has a unique mode of glycosphingolipid antigen recognition Proc. Natl. Acad. Sci. U. S. A. 101 2004 12254 12259
40. J.R. Ortaldo Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides J. Immunol. 172 2004 943 953
41. V.V. Parekh Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids J. Immunol. 173 2004 3693 3706
42. A.R. Castano Peptide binding and presentation by mouse CD1 Science 269 1995 223 226
43. R.D. Goff Effects of Lipid Chain Lengths in á-Galactosylceramides on Cytokine Release by Natural Killer T Cells J. Am. Chem. Soc. 126 2004 13602 13603
44. A. Chiba Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha- galactosylceramide Arthritis Rheum. 50 2004 305 313
45. T. Yamamura NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease Curr. Top. Med. Chem. 4 2004 561 567
46. D.E. Levy, and C. Tang The Chemistry of C-Glycosides 1995 Elsevier Science Ltd
47. M.H.D. Postema C-Glycoside Synthesis 1995 CRC Press, Inc.
48. S. Oki The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells J. Clin. Invest. 113 2004 1631 1640
49. C. Cantu III The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs J. Immunol. 170 2003 4673 4682
50. V. Costantino Immunomodulating glycosphingolipids: an efficient synthesis of a 2′-deoxy-galactosyl-GSL Tetrahedron 58 2002 369 375
51. G.A. Lang Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts Immunology 112 2004 386 396
52. S. Munro Lipid rafts: elusive or illusive? Cell 115 2003 377 388
53. W.J. van Blitterswijk Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem. J. 369 2003 199 211
54. D. Zhou Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins Science 303 2004 523 527
55. J.D. Silk Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy J. Clin. Invest. 114 2004 1800 1811